CAR T-cell therapy IMPT-514 gets FDA fast track designation for lupus
The U.S. Food and Drug Administration (FDA) has granted fast track designation to IMPT-514, a CAR T-cell therapy being developed by Immpact Bio for people with active, treatment-resistant lupus nephritis and systemic lupus erythematosus (SLE). Lupus nephritis is a serious complication of lupus characterized by kidney inflammation.